🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
Lupus nephritis (LN) develops in 30-60% of systemic lupus erythematosus (SL...
Status
Not Yet Recruiting
Location
Multiple Locations
Start Date
2026-04-01
Trial ID
NCT07505576
The investigators are trying to understand the role of DNA (deoxyribonuclei...
Status
Completed
Location
University of Arizona
Start Date
2016-11
Trial ID
NCT03259984
The goal of this observational study is to assess the effectiveness of the ...
Status
Recruiting
Location
Kingston Health Sciences Centre - Cancer Centre of Southeastern Ontario
Start Date
2023-10-19
Trial ID
NCT05804578
Application of circulating tumor DNA detection in diagnosis and treatment o...
Status
Unknown
Location
Zhejiang Cancer Hospital
Start Date
2017-07-19
Trial ID
NCT03615170
The researchers are doing this study to measure and test cell-free DNA (cfD...
Status
Active Not Recruiting
Location
Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
Start Date
2020-07-08
Trial ID
NCT04468841
Deoxyribonucleic acid (DNA) damage of granulosa cells obtained during oocyt...
Status
Unknown
Location
Multiple Locations
Start Date
2022-10-01
Trial ID
NCT05558046
The overall goal of this study is to inform the design and establish feasib...
Status
Not Yet Recruiting
Location
Botswana Harvard Health Partnership
Start Date
2026-06-01
Trial ID
NCT07576842
The purpose of this pragmatic cluster randomized control trial is to test t...
Status
Completed
Location
Uganda Cancer Institute
Start Date
2019-08-01
Trial ID
NCT04000503
Treatments Being Tested
The purpose of this study is to determine whether it is possible to predict...
Status
Terminated
Location
Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital
Start Date
2011-05
Trial ID
NCT01855061
Treatments Being Tested
Primary Objective: • To evaluate the safety and tolerability of cAd3-EBO-S...
Status
Completed
Location
Oklahoma Blood Institute (OBI)
Start Date
2021-01-06
Trial ID
NCT04723602
Treatments Being Tested